Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.

• Source: investors.adverum
• 475
• January 31, 2018